Negative in Ames, in vitro chromosomal aberration and mouse bone marrow micronucleus assays
“No genotoxic potential was identified in the standard battery of genotoxic toxicology, including in vitro Ames and chromosomal aberration assays, and in vivo bone marrow micronucleus assay in mice (Module 4.2.3.3).”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“No carcinogenicity studies were conducted. These studies were not required for an oncology drug intended for treatment of patients with severe or life-threatening malignancies per ICH S9 guidance.”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Mouse and rabbit EFD: malformations in rabbits at high dose; post-implantation loss and lower fetal weight in mice
“Abnormalities included external, visceral, and skeletal malformations observed in the high dose group.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Safety pharmacology
No hERG effect; no cardiovascular effects in dogs up to 100 mg/kg; no CNS effects in mice up to 300 mg/kg
“Based on findings from non-GLP and GLP assays, sonrotoclax had no effect on the human Ether-a-go-go-Related Gene (hERG) channel in Chinese Hamster Ovary cells. Sonrotoclax had no effect on cardiovascular parameters in dogs after single or repeated doses of up to 100 mg/kg or on central nervous system parameters in mice after repeated doses of up to 300 mg/kg.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗
Genotox: Ames
Negative (Ames)
“Sonrotoclax was not mutagenic in a bacterial mutagenicity (Ames) assay and not clastogenic in a chromosome aberration assay in mammalian cells or in an in vivo bone marrow micronucleus assay in mice.”
Chromosome aberration assay in mammalian cells: negative
“Sonrotoclax was not mutagenic in a bacterial mutagenicity (Ames) assay and not clastogenic in a chromosome aberration assay in mammalian cells or in an in vivo bone marrow micronucleus assay in mice.”
“Sonrotoclax was not mutagenic in a bacterial mutagenicity (Ames) assay and not clastogenic in a chromosome aberration assay in mammalian cells or in an in vivo bone marrow micronucleus assay in mice.”
“No carcinogenicity studies were conducted. These studies were not required for an oncology drug intended for treatment of patients with severe or life-threatening malignancies per ICH S9 guidance.”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
Carcinogenicity timing
Not required for an oncology drug for severe or life-threatening malignancies (ICH S9); none conducted
“No carcinogenicity studies were conducted. These studies were not required for an oncology drug intended for treatment of patients with severe or life-threatening malignancies per ICH S9 guidance.”
✓ VerifiedFDA multi-discipline review, p. 52Source ↗
hERG / QT
No meaningful hERG inhibition; margin >430-fold vs human unbound Cmax at 320 mg/day
“Sonrotoclax did not show meaningful inhibition of the hERG channel at the highest soluble concentration tested, with a safety margin > 430-fold relative to the human unbound Cmax at the clinical dose (320 mg/day) (Study 180-0750-EP).”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative